Accelerate Diagnostics Company Profile (NASDAQ:AXDX)

About Accelerate Diagnostics (NASDAQ:AXDX)

Accelerate Diagnostics logoAccelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AXDX
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.5148 billion
  • Outstanding Shares: 52,034,000
Average Prices:
  • 50 Day Moving Avg: $28.00
  • 200 Day Moving Avg: $25.29
  • 52 Week Range: $19.20 - $30.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -30.67
  • P/E Growth: -0.78
Sales & Book Value:
  • Annual Revenue: $612,999.00
  • Price / Sales: 2,342.81
  • Book Value: $1.33 per share
  • Price / Book: 20.75
  • EBIDTA: ($63,330,000.00)
  • Net Margins: -11,158.43%
  • Return on Equity: -76.35%
  • Return on Assets: -71.90%
  • Current Ratio: 13.42%
  • Quick Ratio: 12.59%
  • Average Volume: 316,883 shs.
  • Beta: 1.98
  • Short Ratio: 22.58
Frequently Asked Questions for Accelerate Diagnostics (NASDAQ:AXDX)

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) posted its quarterly earnings results on Friday, May, 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.07. The business had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.60 million. Accelerate Diagnostics had a negative return on equity of 76.35% and a negative net margin of 11,158.43%. View Accelerate Diagnostics' Earnings History.

When will Accelerate Diagnostics make its next earnings announcement?

Accelerate Diagnostics is scheduled to release their next quarterly earnings announcement on Monday, August, 7th 2017. View Earnings Estimates for Accelerate Diagnostics.

What guidance has Accelerate Diagnostics issued on next quarter's earnings?

Accelerate Diagnostics updated its first quarter earnings guidance on Wednesday, May, 3rd. The company provided earnings per share guidance of ($0.27) for the period, compared to the Thomson Reuters consensus estimate of ($0.35). The company issued revenue guidance of $530000, compared to the consensus revenue estimate of $1.31 million.

Where is Accelerate Diagnostics' stock going? Where will Accelerate Diagnostics' stock price be in 2017?

3 brokerages have issued twelve-month price targets for Accelerate Diagnostics' stock. Their forecasts range from $25.00 to $34.00. On average, they expect Accelerate Diagnostics' stock price to reach $30.33 in the next year. View Analyst Ratings for Accelerate Diagnostics.

Who are some of Accelerate Diagnostics' key competitors?

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the folowing people:

  • John Patience, Independent Chairman of the Board
  • Lawrence Mehren, President, Chief Executive Officer, Director
  • Steve Reichling, Chief Financial Officer
  • Joan Martin, Executive Vice President & Head of Europe, Middle East, and Africa
  • Ron Price, Senior Vice President and Head of Commercial Operations, Americas
  • Tom Brown, Independent Director
  • Mark C. Miller, Independent Director
  • Jack W. Schuler, Independent Director
  • Matthew W. Strobeck Ph.D., Independent Director
  • Frank J M ten Brink, Independent Director

How do I buy Accelerate Diagnostics stock?

Shares of Accelerate Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Accelerate Diagnostics' stock price today?

One share of Accelerate Diagnostics stock can currently be purchased for approximately $27.60.

MarketBeat Community Rating for Accelerate Diagnostics (NASDAQ AXDX)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  78 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  133
MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Accelerate Diagnostics (NASDAQ:AXDX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $30.33 (9.90% upside)

Analysts' Ratings History for Accelerate Diagnostics (NASDAQ:AXDX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/12/2017BTIG ResearchReiterated RatingBuy -> Buy$34.00HighView Rating Details
6/5/2017Piper Jaffray CompaniesReiterated RatingOverweight$30.00 -> $32.00LowView Rating Details
8/9/2016J P Morgan Chase & CoBoost Price TargetOverweight$17.00 -> $25.00N/AView Rating Details
1/29/2016William BlairReiterated RatingBuyN/AView Rating Details
(Data available from 7/22/2015 forward)


Earnings History for Accelerate Diagnostics (NASDAQ:AXDX)
Earnings by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)
Earnings History by Quarter for Accelerate Diagnostics (NASDAQ AXDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017($0.30)N/AView Earnings Details
5/5/2017Q1($0.34)($0.27)$0.60 million$0.50 millionViewListenView Earnings Details
2/27/2017Q4 2016($0.35)($0.31)$0.24 million$0.04 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.35)($0.34)$0.02 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Accelerate Diagnostics (NASDAQ:AXDX)
2017 EPS Consensus Estimate: ($1.29)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.34)($0.34)($0.34)
Q2 20171($0.34)($0.34)($0.34)
Q3 20171($0.31)($0.31)($0.31)
Q4 20171($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)


Dividend History for Accelerate Diagnostics (NASDAQ:AXDX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Accelerate Diagnostics (NASDAQ:AXDX)
Insider Ownership Percentage: 51.40%
Institutional Ownership Percentage: 37.34%
Insider Trades by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)
Institutional Ownership by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)
Insider Trades by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/21/2017Steven ReichlingInsiderSell30,000$28.90$867,000.00View SEC Filing  
1/9/2017Lawrence MehrenInsiderSell400,068$19.00$7,601,292.00View SEC Filing  
1/9/2017Matthew StrobeckDirectorBuy8,000$19.00$152,000.00View SEC Filing  
6/30/2016Jack W SchulerDirectorBuy90,147$13.95$1,257,550.65View SEC Filing  
6/14/2016Jack W SchulerDirectorBuy14,033$13.67$191,831.11View SEC Filing  
6/13/2016Jack W SchulerDirectorBuy15,967$13.70$218,747.90View SEC Filing  
6/10/2016Jack W SchulerDirectorBuy88,316$14.69$1,297,362.04View SEC Filing  
6/9/2016Jack W SchulerDirectorBuy101,272$14.14$1,431,986.08View SEC Filing  
5/20/2016Jack W SchulerDirectorBuy4,270$11.04$47,140.80View SEC Filing  
5/17/2016Jack W SchulerDirectorBuy10,000$11.45$114,500.00View SEC Filing  
5/16/2016Jack W SchulerDirectorBuy11,511$11.91$137,096.01View SEC Filing  
5/13/2016Jack W SchulerDirectorBuy20,000$12.45$249,000.00View SEC Filing  
2/9/2016Jack W SchulerDirectorBuy600,000$11.86$7,116,000.00View SEC Filing  
2/8/2016Jack W SchulerDirectorBuy20,000$12.32$246,400.00View SEC Filing  
2/5/2016Jack W SchulerDirectorBuy7,308$12.65$92,446.20View SEC Filing  
2/4/2016Jack W SchulerDirectorBuy10,000$12.98$129,800.00View SEC Filing  
2/3/2016Jack W SchulerDirectorBuy50,100$13.09$655,809.00View SEC Filing  
2/2/2016Jack W SchulerDirectorBuy20,000$13.46$269,200.00View SEC Filing  
1/21/2016Jack W SchulerDirectorBuy10,000$15.02$150,200.00View SEC Filing  
12/10/2015Larry N FeinbergMajor ShareholderBuy117,647$17.00$1,999,999.00View SEC Filing  
11/5/2015Jack W SchulerDirectorBuy11,899$16.81$200,022.19View SEC Filing  
11/4/2015Jack W SchulerDirectorBuy52,837$16.81$888,189.97View SEC Filing  
10/22/2015Jack W SchulerDirectorBuy2,160$15.82$34,171.20View SEC Filing  
9/29/2015Brink Frank Jm TenDirectorBuy9,800$15.24$149,352.00View SEC Filing  
8/26/2015Jack W SchulerDirectorBuy10,000$17.81$178,100.00View SEC Filing  
8/25/2015Jack W SchulerDirectorBuy10,000$18.56$185,600.00View SEC Filing  
4/17/2015Jack W SchulerDirectorBuy11,000$21.94$241,340.00View SEC Filing  
3/19/2015Matthew StrobeckDirectorBuy2,000$22.04$44,080.00View SEC Filing  
3/9/2015Jack W SchulerDirectorBuy22,584$17.18$387,993.12View SEC Filing  
1/5/2015Jack W SchulerDirectorBuy18,000$18.93$340,740.00View SEC Filing  
9/22/2014Jack W SchulerDirectorBuy2,588$16.44$42,546.72View SEC Filing  
9/19/2014Jack W SchulerDirectorBuy32,411$16.67$540,291.37View SEC Filing  
8/21/2014Jack W SchulerDirectorBuy2,900$16.79$48,691.00View SEC Filing  
8/5/2014Larry N FeinbergMajor ShareholderBuy11,835$15.92$188,413.20View SEC Filing  
8/5/2014Matthew StrobeckDirectorBuy20,000$16.70$334,000.00View SEC Filing  
8/4/2014Matthew StrobeckDirectorBuy20,000$16.70$334,000.00View SEC Filing  
7/16/2014Larry N FeinbergMajor ShareholderBuy20,000$21.54$430,800.00View SEC Filing  
7/1/2014Jack W SchulerDirectorBuy8,698$25.70$223,538.60View SEC Filing  
6/30/2014Jack W SchulerDirectorBuy10,000$26.09$260,900.00View SEC Filing  
6/30/2014Larry N FeinbergMajor ShareholderBuy20,000$25.72$514,400.00View SEC Filing  
5/12/2014Larry N FeinbergMajor ShareholderBuy297,618$16.80$4,999,982.40View SEC Filing  
2/5/2014Larry N FeinbergMajor ShareholderBuy8,554$24.78$211,968.12View SEC Filing  
1/27/2014Larry N FeinbergMajor ShareholderBuy16,307$13.09$213,458.63View SEC Filing  
12/31/2013Larry N FeinbergMajor ShareholderBuy84,081$12.29$1,033,355.49View SEC Filing  
10/30/2013Larry N FeinbergMajor ShareholderBuy10,000$12.95$129,500.00View SEC Filing  
8/30/2013Larry N FeinbergMajor ShareholderBuy16,001$9.76$156,169.76View SEC Filing  
8/28/2013Larry N FeinbergMajor ShareholderBuy158,445$9.80$1,552,761.00View SEC Filing  
8/16/2013Jack W SchulerDirectorBuy78,494$7.88$618,532.72View SEC Filing  
8/14/2013Jack W SchulerDirectorBuy413,090$8.04$3,321,243.60View SEC Filing  
8/14/2013Larry N FeinbergMajor ShareholderBuy36,814$7.24$266,533.36View SEC Filing  
8/9/2013Larry N FeinbergMajor ShareholderBuy35,168$7.30$256,726.40View SEC Filing  
6/21/2013Larry N FeinbergMajor ShareholderBuy114,250$8.00$914,000.00View SEC Filing  
6/12/2013Larry N FeinbergMajor ShareholderBuy7,175$8.41$60,341.75View SEC Filing  
6/7/2013Larry N FeinbergMajor ShareholderBuy45,508$8.33$379,081.64View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Accelerate Diagnostics (NASDAQ:AXDX)
Latest Headlines for Accelerate Diagnostics (NASDAQ:AXDX)
DateHeadline logoCommit To Purchase Accelerate Diagnostics At $25, Earn 28.8% Annualized Using Options - July 21 at 5:51 PM logoAccelerate Diagnostics Schedules Call to Review Second Quarter 2017 Results for August 3rd - GlobeNewswire (press release) - July 18 at 10:47 PM logoAccelerate Diagnostics Schedules Call to Review Second Quarter 2017 Results for August 3rd - July 18 at 5:47 PM logoAccelerate Diagnostics, Inc. (AXDX) Lifted to "Buy" at BidaskClub - July 16 at 4:00 PM logoETFs with exposure to Accelerate Diagnostics, Inc. : July 14, 2017 - July 14 at 6:08 PM logoAccelerate Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : AXDX-US : July 12, 2017 - July 12 at 4:50 PM logoZacks: Accelerate Diagnostics, Inc. (AXDX) Receives Consensus Recommendation of "Strong Buy" from Analysts - July 10 at 2:30 PM logoWireless Sensing Technologies Energize Oil and Gas Pipeline Monitoring Sector - July 9 at 4:17 PM logoAccelerate Diagnostics, Inc. (NASDAQ:AXDX) Cut to "Hold" at Zacks Investment Research - July 4 at 5:56 PM logoAccelerate Diagnostics, Inc. (NASDAQ:AXDX) Rating Lowered to Hold at BidaskClub - July 1 at 7:32 PM logoBioScrip (BIOS) Strong on Infusion, Reimbursement a Drag - June 30 at 4:20 PM logoWalgreens Boots-LabCorp Tie Up for Patient Service Centers - June 29 at 5:21 PM logoQuest Diagnostics to Buy Outreach Lab Service in Cape Cod - Nasdaq - June 29 at 2:30 AM logoAccelerate Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : AXDX-US : June 28, 2017 - June 28 at 4:26 PM logoThermo Fisher Gets FDA's PMA for Oncomine Dx Target Test - June 27 at 3:54 PM logo3 Reasons Why Accelerate Diagnostics (AXDX) is a Great Momentum Stock - June 27 at 3:54 PM logoConforMIS (CFMS) Gets FDA Approval for iTotal Hip System - Nasdaq - June 26 at 4:22 PM logoAccelerate Diagnostics, Inc. (AXDX) Upgraded to Buy by BidaskClub - June 23 at 11:28 PM logoWhy Investors Should Buy Align Technology (ALGN) Right Now - Nasdaq - June 23 at 9:25 PM logoInsider Selling: Accelerate Diagnostics, Inc. (AXDX) Insider Sells 30,000 Shares of Stock - June 23 at 7:15 PM logoZacks: Accelerate Diagnostics, Inc. (AXDX) Receives Consensus Rating of "Strong Buy" from Analysts - June 23 at 11:27 AM logoLantheus (LNTH) Scores a Strong Buy Right Now: Here's How - June 22 at 8:55 PM logoBio-Rad (BIO) Scores a Strong Buy Right Now: Here's How - June 22 at 3:52 PM logoLantheus (LNTH) Scores a Strong Buy Right Now: Here's How - Nasdaq - June 22 at 11:58 AM logoBio-Rad (BIO) Scores a Strong Buy Right Now: Here's How - Nasdaq - June 22 at 11:58 AM logoWhy Quest Diagnostics (DGX) is a Suitable Pick for Investors - Nasdaq - June 22 at 11:58 AM logoHere's Why Henry Schein is Worth Adding to Your Portfolio - June 22 at 11:58 AM logoWhy Hold Strategy is Apt for Thermo Fisher (TMO) Stock Now - June 22 at 11:58 AM logoGenomic Health Cancer Tests Strong, Operating Expenses a Woe - Nasdaq - June 21 at 4:40 PM logoMedtronic CRT Devices Improve Therapy Delivery, Cut Costs - Nasdaq - June 21 at 4:40 PM logoPAREXEL to Launch Connected Journey Data-Driven Services - June 20 at 4:24 PM logoResMed (RMD) at 52-Week High: What's Driving the Stock? - June 20 at 4:24 PM logoLuminex (LMNX) Scores a Strong Buy Right Now: Here's How - June 20 at 4:24 PM logoHologic Receives Extended FDA Clearance for SculpSure in US - June 19 at 9:44 AM logoInogen (INGN) Scores a Strong Buy Right Now: Here's How - June 19 at 9:44 AM logoAccelerate Diagnostics Sees Unusually High Options Volume (AXDX) - June 18 at 7:04 AM logoWhy Does Intuitive Surgical Score as a Strong Buy Right Now - Nasdaq - June 16 at 9:29 PM logoDaVita (DVA) Rolls Out Alliance Site Network for CKD Trial - Nasdaq ... - Nasdaq - June 16 at 4:28 PM logoETFs with exposure to Accelerate Diagnostics, Inc. : June 15, 2017 - June 15 at 10:36 PM logoAbbott Laboratories Up on EPD & Buyouts, Pediatric Weak - Nasdaq - June 15 at 5:31 PM logoHenry Schein Grows on Strategic Buyouts, Competition Rife - Nasdaq - June 15 at 5:31 PM logoHere's Why Phibro Animal Health Is Worth Buying Right Now - Nasdaq - June 15 at 5:31 PM logoLabCorp to Grow in Precision Med with Cancer Diagnostics Lab ... - Nasdaq - June 15 at 5:31 PM logoMedtronic Resource Centre Opens for Diabetic People in Canada - Nasdaq - June 14 at 8:57 PM logoFDA Passes Zimmer Biomet's (ZBH) Zhejiang Facility Issue - Nasdaq - June 14 at 3:55 PM logoAccelerate Diagnostics, Inc. – Value Analysis (NASDAQ:AXDX) : June 14, 2017 - June 14 at 3:55 PM logoBecton (BDX) with FlowJo to Provide Cloud Platform Services - June 14 at 10:19 AM logoFDA Passes Zimmer Biomet's (ZBH) Zhejiang Facility Issue - June 14 at 10:19 AM logoHill-Rom Rides High on Solid Prospects, Asia-Pacific a Drag - June 14 at 10:18 AM logoMedtronic Resource Centre Opens for Diabetic People in Canada - June 14 at 10:18 AM



Accelerate Diagnostics (AXDX) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff